Kodiak Sciences (NYSE:KOD) issued its earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.16, MarketWatch Earnings reports.
Shares of NYSE:KOD traded up $0.66 during midday trading on Thursday, reaching $8.16. 5,226 shares of the company’s stock were exchanged, compared to its average volume of 67,146. Kodiak Sciences has a fifty-two week low of $5.65 and a fifty-two week high of $11.10.
KOD has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Kodiak Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 2nd. Chardan Capital initiated coverage on Kodiak Sciences in a research report on Wednesday, February 20th. They set a “buy” rating and a $22.50 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Kodiak Sciences has an average rating of “Buy” and a consensus target price of $19.13.
A hedge fund recently bought a new stake in Kodiak Sciences stock. Geode Capital Management LLC bought a new stake in shares of Kodiak Sciences Inc. (NYSE:KOD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 64,561 shares of the company’s stock, valued at approximately $458,000. Geode Capital Management LLC owned 0.18% of Kodiak Sciences at the end of the most recent reporting period.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2019/05/16/kodiak-sciences-kod-releases-earnings-results.html.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
See Also: The Structure of a Futures Contract
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.